Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Researchers use biotechnological tools to find a cure for Alzheimer's disease

No one has yet found a cure or a way to prevent people from developing Alzheimer's disease. Researchers from the Swedish University of Agricultural Sciences, among others, are breaking new ground in biotechnology to find new tools that can help provide new solutions.

20 Oct 2009

Conference to discuss the pent-up demand for home based eldercare personal robots

GeckoSystems Intl. Corp. announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009, attendees will be able to learn and discuss the basis for GeckoSystems' belief that pent-up demand exists for their cost effective, home based eldercare personal robots.

20 Oct 2009

PhRMA calls for appropriate incentives for continued biotechnology innovation

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:

20 Oct 2009

Scientists find mechanism that protects neurons from calcium overload

Tsuruta et al. find that a lipid kinase directs a voltage-gated calcium channel's degradation to save neurons from a lethal dose of overexcitement. The study appears in the October 19, 2009 issue of the Journal of Cell Biology (www.jcb.org).

20 Oct 2009

Researchers develop new technique to study the mechanisms behind diseases in more detail

Researchers have previously been able to analyse which sugar structures are to be found on certain proteins, but not exactly where on the protein they are positioned. This is now possible thanks to a new technique developed at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Antioxidant extracts of the leaves of the Gingko biloba tree may protect cells from radiation damage, according to a study published in the International Journal of Low Radiation. The discovery may one day be used to help reduce side effects in cancer patients undergoing radiotherapy.

20 Oct 2009

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques-considered a hallmark of the disease-from patients' brains.

19 Oct 2009

Researchers find the genetic mutation that is linked with changes in brain development

For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept(10 mg).

19 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Windsor Place of Wilmington opens to welcome new residents

Windsor Place of Wilmington, a premier assisted living residence for seniors, announced today that it will welcome residents this month. Windsor Place has 87 distinctive luxury suites. A portion are designated for individuals with memory impairment due to Alzheimer’s disease and related disorders.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

NIH awards research grants for NYU Langone Medical Center

NYU Langone Medical Center has been awarded more than $30 million in research grants from the National Institute of Health (NIH) for 86 research projects being conducted at NYU School of Medicine across a broad range of basic science and clinical departments.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Alzheimer's Disease News and Research

Further Reading

Targacept presents data from Phase 2b clinical trial of TC-5214

Researchers use biotechnological tools to find a cure for Alzheimer's disease

Conference to discuss the pent-up demand for home based eldercare personal robots

PhRMA calls for appropriate incentives for continued biotechnology innovation

Scientists find mechanism that protects neurons from calcium overload

Researchers develop new technique to study the mechanisms behind diseases in more detail

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

Researchers find the genetic mutation that is linked with changes in brain development

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

APP balance critical for normal neuronal development

Windsor Place of Wilmington opens to welcome new residents

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

NIH awards research grants for NYU Langone Medical Center

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News